Atlas Trials

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

Clinical trial NCT04605094 · TERMINATED

Trial details

NCT number
NCT04605094
Sponsor
AstraZeneca
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Atopic Dermatitis
Start date
2020-11-12
Primary completion
2022-04-25
Enrollment
194

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.